Liking GTXI on the Monday Open

Hello Readers and New Subscribers,

As everyone enjoyed their weekend, we touted our 6 stock picks from last week and we watched a huge mover on Friday, GTx, Inc. (NASDAQ: GTXI).

The stock was upgraded Friday morning and surged over 20%.  There ids still a lot of room to profit on this Hormone Development Biopharmaceutical company since analysts are targeting $7.

The company markets FARESTON (toremifene citrate) 60 mg tablets for the treatment of metastatic breast cancer in postmenopausal women through wholesale drug distributors in the United States. It is developing Toremifene citrate 80 mg, which completed pivotal Phase III clinical trial to reduce fractures and treat other estrogen deficiency side effects of androgen deprivation therapy in men with prostate cancer; and Toremifene 20 mg that is in pivotal Phase III clinical trial for the prevention of prostate cancer in high risk men with precancerous prostate lesions called high grade prostatic intraepithelial neoplasia.

We like this company in the short term and think it will be a good play this week.

We have a featured pick due out later in the week so stay tuned to our newsletters and always Target Your Profits Higher.

Last updated by at .